ISSN 1016-5169 | E-ISSN 1308-4488
pdf
The serum pentraxin-3 is elevated in patients with cardiac syndrome X [Turk Kardiyol Dern Ars]
Turk Kardiyol Dern Ars. 2013; 41(4): 290-295 | DOI: 10.5543/tkda.2013.20025

The serum pentraxin-3 is elevated in patients with cardiac syndrome X

Eyüp Büyükkaya1, Mehmet Fatih Karakaş1, Mustafa Kurt1, Sedat Motor2, Adnan Burak Akcay1, Şule Büyükkaya3, Esra Karakaş4, Nihat Şen1
1Department of Cardiology, Mustafa Kemal University Tayfur Ata Sokmen Faculty of Medicine, Hatay, Turkey
2Department of Clinical Biochemistry, Mustafa Kemal University Tayfur Ata Sokmen Faculty of Medicine, Hatay, Turkey
3Department of Endocrinology and Metabolism, Mustafa Kemal University Tayfur Ata Sokmen Faculty of Medicine, Hatay, Turkey
4Department of Cardiology, Antakya State Hospital, Hatay, Turkey


OBJECTIVES
Cardiac syndrome X (CSX) is a clinical entity that is defined as normal coronary arteries with angina pectoris and objective sins of ischemia. The correlation between CSX and inflammatory markers such as high-sensitivity C-reactive protein (hs-CRP) is well established, however an association with pentraxin- 3 (PTX-3) has not been examined. The aim of this study was to investigate the association between PTX-3 and CSX.

STUDY DESIGN
A total of 122 patients (58 female, 64 male, mean age 49.6±5.8 years) with suspected of coronary artery disease (CAD) were included in the study. Those with evidence of ischemia (50 patients with positive treadmill tests, 32 patients with positive myocardial perfusion scintography) underwent coronary angiography (82 patients). Patients with a normal angiogram were considered the CSX group (n=41) and patients with coronary lesions were referred to as the CAD group (n=41). Patients without signs of ischemia served as the control group. Serum PTX-3 and hs-CRP levels were measured in all patients.

RESULTS
The CSX group had significantly increased PTX-3 levels relative to the control group (0.46±0.16 vs. 0.23±0.09 ng/ml, p<0.001). However there were no differences in levels of PTX-3 and hs-CRP between the CSX and the CAD groups (PTX-3: 0.46±0.16 vs. 0.51±0.13 ng/ml, p=0.21; hs- CRP: 1.04±0.45 vs. 1.16±0.64 mg/dl, p=0.62). The control group had significantly lower hs-CRP levels (0.73±0.51 mg/ dl) when compared to the both CSX and CAD groups (p=0.03 and p=0.002, respectively). Serum PTX-3 levels were weakly correlated with hs-CRP levels (r=0.30, p=0.001).

CONCLUSION
PTX-3, a novel inflammatory marker, is elevated in patients with CSX, similar to the well known inflammatory marker hs-CRP, and may be a promising biomarker reflecting inflammatory status in these patients.

Keywords: Angina pectoris/etiology, cardiac syndrome X; C-reactive protein; coronary angiography; coronary artery disease; PTX3 protein; syndrome.

How to cite this article
Eyüp Büyükkaya, Mehmet Fatih Karakaş, Mustafa Kurt, Sedat Motor, Adnan Burak Akcay, Şule Büyükkaya, Esra Karakaş, Nihat Şen. The serum pentraxin-3 is elevated in patients with cardiac syndrome X. Turk Kardiyol Dern Ars. 2013; 41(4): 290-295

Corresponding Author: Eyüp Büyükkaya, Türkiye
Manuscript Language: English


Journal Metrics

Journal Citation Indicator: 0.18
CiteScore: 1.1
Source Normalized Impact
per Paper:
0.22
SCImago Journal Rank: 0.348

Quick Search



Copyright © 2024 Archives of the Turkish Society of Cardiology



Kare Publishing is a subsidiary of Kare Media.